Guidant's Loss of Innocence

Since its 1994 spin off, Guidant has built itself into one of the leading cardiovascular device companies through a deft technology innovation. But a series of recent missteps, most visibly in its AAA graft business but most importantly in its drug-eluting stent business, has caused this former start-up to grow up quickly. But Guidant officials counter that the AAA problems will quickly be put behind and that the drug-eluting stent program will emerge a winner, every bit as strong as its traditional bare metal stent business and its currently robust cardiac rhythm management business.

By David Cassak

Things like this weren't supposed to happen.

More from Leadership

More from In Vivo

Geopolitical Volatility Not Dimming A Healthy Mid-Term Outlook For Life Sciences Deals

 
• By 

New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.

Navigating the GLP-1 Opportunity In China: Strategic Imperatives For Western Pharma

 
• By 

The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.

Strategic Surprises: The Drugs That Rewrote The Forecasts

 

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.